Key result
Non-vitamin K antagonist oral anticoagulants (NOACs) and their reversibility are the subject of this response, though no clinical findings are reported in the provided abstract.
Key points are not available for this paper at this time.
Reversibility gaps in NOAC bleeding management warrant clinical caution; leaves open the need for targeted reversal trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Kaba et al. (2014) studied this question. Non-vitamin K antagonist oral anticoagulants (NOACs) and their reversibility are the subject of this response, though no clinical findings are reported in the provided abstract.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: